Followers | 129 |
Posts | 23648 |
Boards Moderated | 1 |
Alias Born | 09/14/2016 |
Friday, March 22, 2019 1:05:49 PM
As accuracy of the GDF15 biomarker is further affirmed, it could ultimately be used as a surrogate biomarker to ocular therapy clinical trial endpoints—perhaps even used as a primary endpoint in MAN-01 trials and studies. In this scenario, major pharmaceuticals engaging in glaucoma or tangentially-related glaucoma or ocular clinical trials may elect to license the biomarker so that they may have access to it for the trials.
By leveraging a single platform, QBIO has multiple shots on goal with respect to market share, revenue and profit in the multi-billion dollar glaucoma market. A unique player on the path to offering a series of "firsts", QBIO is leading innovation in the lucrative ophthalmology segment, which carries high price/revenue multiples.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM